Discovery and Activity of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian and Endometrial Cancer
Xiaofan Li, Cristina Abrahams, Sihong Zhou, Stefania Krimmel, Benjamin Steffens, Jeffrey Hanson, Mary Rose Masikat, Krishna Bajjuri, Tyler Heibeck, Cuong Tran, Gang Yin, Xiaofan Li, Cristina Abrahams, Sihong Zhou, Stellanie Krimm, Robert Henningsen, Heather Stephenson, Jeffrey Hanson, Mary Rose Masikat, Krishna Bajjuri, Tyler Heibeck, Cuong Tran, Gang Yin, Sutro Biopharma, South San Francisco, CA, USA

Introduction
- Folate receptor alpha (FRα) is a cell-surface protein overexpressed in ovarian and endometrial cancers.
- Folate expression is highly restricted on normal tissues, making it a promising target for cancer therapy

Selection of Optimum Drug-Linker and DAR
ADC with a Cleavable Drug-Linker at DAR 4 Showed Best Activity

Optimization of Cell-Free Technology
- We have leveraged Sutro’s proprietary XpressCF+™ cell-free expression system and site-specific conjugation to design novel Folate-targeting ADC, STRO-002.

References